Insulinogenic Index
3 papers1 finding
- Human trial2
- Humans1
Interventions
1AT7687
downin humans1
1 study
AT7687
downin humans1
AT7687 decreases Insulinogenic Index in humans (SAD p=0.009, MAD p=0.029).
“AT led to statistically significant change in post- minus pre-dose Insulinogenic Index in both SAD (p=0.009) and MAD (p=0.029)”
Human trialSAD and MAD cohortsup to Day 29
ADA Scientific Sessions 2026 abstract7 Jun 2026
Latest
1 in 12 monthsADA Scientific Sessions 2026 Abstract
First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity
Randomised trial in peopleObesity
ADA Scientific Sessions 2025 Abstract
A Low-Carbohydrate, Low—Saturated Fat Diet to Treat β-Cell Dysfunction and Insulin Resistance in Asian Indians with Prediabetes—A 24-Week Randomized Trial
Randomised trial in 53 peoplePrediabetes
ADA Scientific Sessions 2025 Abstract
Eight-Year Trajectories of Oral Glucose Tolerance Tests and Liver Enzymes in Nonobese Japanese Physical Examination Participants
Cohort study of 105 peoplePopulations
Diabetes & Metabolism Journal
Anti-Senescence Effect of Inhibiting Sodium-Glucose Cotransporter 2 and α-Glucosidase in a Type 2 Diabetes Mellitus Animal Model
Experiments in animalsInterventions